Iopidine

Apraclonidine, the active ingredient in Iopidine, is a Alpha-2 adrenergic agonist presented as a 0.5% w/v ophthalmic solution for ocular (topical) use. It treats open-angle glaucoma and ocular hypertension by lowering intra‑ocular pressure.

GNH USA supplies Iopidine as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iopidine (apraclonidine) is used in the management of ocular conditions that involve elevated intra‑ocular pressure.

Open‑angle glaucoma: reduces intra‑ocular pressure and helps prevent optic nerve damage. Ocular hypertension: lowers intra‑ocular pressure to reduce risk of progression to glaucoma. Post‑operative pressure spikes: controls transient pressure elevation after eye surgery.

Common Side Effects: - Ocular burning or stinging sensation. - Redness of the eye. - Blurred vision. - Dry eye or foreign‑body feeling. - Mild conjunctival hyperemia. - Transient pupil dilation.

Serious or Rare Side Effects: - Severe allergic reaction (angioedema, rash). - Significant ocular inflammation or uveitis. - Corneal edema. - Persistent mydriasis. - Systemic hypotension, especially with other alpha‑2 agonists. - Vision loss if severe ocular complications occur.

Before using Iopidine, consider the following precautions: - Hypersensitivity: avoid if allergic to apraclonidine or formulation components. - Narrow‑angle glaucoma: use with caution; monitor intra‑ocular pressure closely. - Cardiovascular disease: be aware of possible systemic hypotensive effects. - Pregnancy: category C; only use if benefit outweighs risk. - Concomitant ocular adrenergic agents: may increase pressure‑lowering effect. - Store at below 25°C: keep in original container, protect from moisture and light.

Iopidine may interact with other medications as follows:

Major Interactions (Avoid): - Systemic alpha‑2 agonists (e.g., clonidine, guanfacine): risk of excessive hypotension. - MAO inhibitors: potential for hypertensive episodes.

Moderate Interactions (Monitor Closely): - Topical beta‑blockers (e.g., timolol): additive intra‑ocular pressure reduction. - Carbonic anhydrase inhibitors (e.g., acetazolamide): enhanced pressure‑lowering effect. - NSAID eye drops: may increase ocular irritation. - Anticholinergic eye drops: possible pupil size changes. - Systemic antihypertensives: monitor for additive blood pressure lowering.